Ocular Drug Delivery Market Poised for Remarkable Growth, to Surpass USD 115.5 Billion by 2032, at 5.5% CAGR | Claims Allied Market Research

The ocular drug delivery market size was valued at $67.7 billion in 2022, and is estimated to reach $115.5 billion by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐃𝐨𝐰𝐧𝐭𝐮𝐫𝐧 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐑𝐞𝐜𝐞𝐬𝐬𝐢𝐨𝐧 𝐢𝐧 2023 𝐨𝐧 𝐭𝐡𝐞 𝐎𝐜𝐮𝐥𝐚𝐫 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭
Ocular drug delivery market is driven by technological advancements in the ocular drug delivery, and rise in prevalence of eye disorders, during recession.
However, increased manufacturing and operating costs, and fluctuations and adverse movement in shipping cost impact the ocular drug delivery market growth during recession.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐨𝐧 𝐎𝐜𝐮𝐥𝐚𝐫 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 2032- www.alliedmarketresearch.com/request-sample/3646

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐧𝐜𝐞 𝐛𝐲 2032
Based on region, North America held the highest market share in terms of revenue in 2022, accounting for nearly half of the global ocular drug delivery market revenue, owing to high research activities in this region, availability of new formulations, and strong presence of market key players. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.3% from 2023 to 2032, owing to development of pharmaceutical industry, and surge in prevalence of geriatric population that are more prone to various eye related disorders.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐎𝐜𝐮𝐥𝐚𝐫 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭
In June 2023, Novaliq GmbH, a pharmaceutical company received the Food and Drug Adminstation (FDA), approval for its VEVYE an opthalmic solution for the treatment of dry eye disease. VEVYE is the first cyclosporine topical solution indicated for the treatment of dry eye
In December 2021, AbbVie Inc., a global pharmaceutical company has received the Food and Drug Administration (FDA) approval for its VUITY eye drop. VUITY eye drop is the first and only approved formulation to treat age-related blurry near vision.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐎𝐜𝐮𝐥𝐚𝐫 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭
In October 2020, Ocular Therapeutix Inc., a global biopharmaceutical company has entered into a collaboration and agreement with AffaMed Therapeutics a clinical-stage biopharmaceutical company. Under this agreement AffaMed Therapeutics will develop and commercialize of DEXTENZA and OTX-TIC in Greater China, South Korea, and the ASEAN markets.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
By technology, the topical segment dominated the global market in 2022.
By formulation type, the solution segment dominated the market in 2022.
By disease indication, the age related macular degeneration segment dominated the global market in 2022.
The North America region dominated the market in terms of revenue in 2022.
Asia-Pacific region is expected to register the highest CAGR during the forecast period.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐅𝐮𝐫𝐭𝐡𝐞𝐫 𝐐𝐮𝐞𝐫𝐢𝐞𝐬 https://www.alliedmarketresearch.com/connect-to-analyst/3646

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: -
Ocular Therapeutix, Inc.
EyePoint Pharmaceuticals, Inc.
Clearside Biomedical
Santen Pharmaceutical Co., Ltd.
Abbvie Inc.
Novaliq GmbH
Bausch & Lomb
Alimera Sciences, Inc.
Nicox
Kiora Pharmaceuticals, Inc.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/ocular-drug-delivery-market

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.